Syncromune

Biotechnology · Health Care

Overview

Syncromune® is developing SYNC-T®, a platform immunotherapy designed to synchronize the location of 3 key components needed to educate the immune system to recognize and attack cancer. Now enrolling LEGION-100 trial for metastatic castration-resistant prostate cancer. www.legion100trial.com.

Funding and backers

Total raised
$159M
2 rounds on record
Latest round
$144.8M
Venture round · Dec 2024 · 23 mo ago
Team
51-200
employees, estimated range
The money's age
Due for its next round
23 months since the last round · not hiring
Momentum
0/100
no fresh signals
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Dec 3, 2024 Raised a round Venture round $144.8M · SEC Form D May 18, 2022 Raised a round Venture round $14.2M · SEC Form D
Funding rounds
RoundDateAmountInvestorsSource
Venture round Dec 2024 $144.8M — SEC Form D
Venture round May 2022 $14.2M — SEC Form D
Registers and programsofficial lists and records that name the company
Legal entity Syncromune, Inc. SEC Form D
Founders and leadersfrom filings, registers and the company's site
Charles LinkExecutive Officer, DirectorSEC Form D
Eamonn HobbsExecutive Officer, DirectorSEC Form D
Joseph GerardiExecutive OfficerSEC Form D
Agustin GagoExecutive OfficerSEC Form D
Kerri-Ann MillarExecutive OfficerSEC Form D
Stephen DaleExecutive OfficerSEC Form D
Investors in similar startupsfunds that back the companies most like this one
Y Combinator
backs Adventris Pharmaceuticals, Kopra Bio
Daphni
backs Neotis
Bayern Kapital
backs T-Curx
Meta Planet
backs Kopra Bio
Multimodal Ventures
backs Kopra Bio
Refactor Capital
backs Adventris Pharmaceuticals
Similar startupsby what they do, their industry and backers
Kopra Bio
Cancer immunotherapy that turns cancer cells into biofactories minting their own destruction.
Lurex BioVenture round $150k · 9 mo ago · Founded 2025
LurexBio is developing a non genetic, non viral recognition engineering platform to address an important component of tumor immune evasion…
Adventris Pharmaceuticals
Adventris Pharmaceuticals is a biotechnology company focusing on cancer immunotherapy.
CellVax TherapeuticsVenture round $2.1M · 2 yr ago · Founded 2020 · 1-10 employees
At CellVax Therapeutics, we are developing the Next Generation of Personalized Immunotherapy.
ALKemist BioVenture round $7.5M · 2 yr ago · 11-50 employees
ALKemist Bio is a biotech startup developing next-generation T cell therapies that target ALK-positive cancers. By reprogramming the immune…
Neotis
Immunotherapiesfor fibrotic disease. Neotis is designing therapies that direct the immune system to eliminate cells driving fibrotic…

Financials

Total raised
$159M
Latest round
Venture - Series Unknown
Funding rounds
2
Funding rounds
Round Announced Amount
Venture - Series Unknown 2024 $144.8M Details
Venture - Series Unknown 2022 $14.2M Details

People

Charles Link
Executive Officer, Director
SEC Form D
Eamonn Hobbs
Executive Officer, Director
SEC Form D
Joseph Gerardi
Executive Officer
SEC Form D
Agustin Gago
Executive Officer
SEC Form D
Kerri-Ann Millar
Executive Officer
SEC Form D
Stephen Dale
Executive Officer
SEC Form D
Joseph Maroon
Director
SEC Form D
Douglas Watson
Director
SEC Form D
Jeffrey Cleland
Director
SEC Form D
Norman Schwartz
Director
SEC Form D
Names and roles come from public filings, company registers and the company's own site. Is this you? Correct or remove · How we handle this data

Offices

Where the company hires and what each office is for
Cities
1
Hiring now
0
Countries
1
Fort Lauderdale United States
HQ
50-200 est. staff